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Diabetes is a common disease aﬀecting majority of populations worldwide. Since 1980, there has been an increase in the number of
people diagnosed as prediabetic and diabetic. Diabetes is characterized by high levels of circulating glucose and leads to most
microvascular and macrovascular complications such as retinopathy, nephropathy, neuropathy, stroke, and myocardial
infarction. Bone marrow vascular disruption and increased adiposity are also linked to various complications in type II diabetes
mellitus. In addition to these complications, type 2 diabetic patients also have fragile bones caused by faulty mineralization
mainly due to increased adiposity among diabetic patients that aﬀects both osteoblast and osteoclast functions. Other factors
that increase fracture risk in diabetic patients are increased oxidative stress, inﬂammation, and drugs administered to diabetic
patients. This review reports the modulation of diﬀerent pathways that aﬀect bone metabolism in diabetic conditions.

1. Introduction
Diabetic patients are at high risk of developing osteoporosis.
Normal to high bone mineral density (BMD) measurements
recorded in type II diabetes mellitus (T2DM) patients are
misleading [1]. In diabetic patients, an increase in the risk
of hip (1.4–1.7-fold) and vertebral fractures have been
reported [2]. As one ages, both genders are not only susceptible to increased risk of fragile bones but are also at high risk
of developing diabetes, which augments the risk of bone fractures [3–6]. Bone fragility in T2DM patients is related to
decreased bone strength and malformation of collagen ﬁbers
that can result in faulty mineralization and increased micro
damages [7–9]. Using BMD measurements alone to diagnose
bone condition in T2DM may not be reliable as the strength
of the bone may be compromised in these patients. It is suggested that BMD with body mass index (BMI) adjustments
may be a better indicator [10]. Supplemental data such as
biochemical markers can be additional diagnostic tool. Bone
biochemical markers such as C-terminal telopeptide (CTX)
and N-terminal telopeptide (NTX) will reﬂect on the bone

resorption process and breakdown of the collagen ﬁbers.
Interestingly, in T2DM patients, there is decreased CTX
and increased NTX levels [11], and other reports did not ﬁnd
any diﬀerence between the two markers [12].
However, in T2DM patients, the quality of collagen ﬁbers
is compromised rather than increased breakdown of the collagen ﬁbers. In T2DM patients, the trabecular bone network
was shown to have large holes, decreased osteoblast recruitment, and mineral apposition rates combined with increased
osteoclastogenesis [13].
The major pathophysiology in T2DM patients is insulin
resistance (IR). This can be attributed to lack of or decreased
insulin secretion and/or insulin receptors on the cell membranes. A close relationship between glucose and bone
metabolism has been reported [14–18]. Yamaguchi and Sugimoto have described the link between glucose, fat, and bone
metabolism [2]. They have suggested that osteocalcin, an
important bone-forming marker, in the uncarboxylated form
and the Wnt signalling pathway proteins, may be modulated
to increase the fragility of bones in diabetic patients [19].
Other hormones secreted by adipocytes like adiponectin
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Figure 1: Insulin signalling pathway in normal cells.

decrease IR [20], while leptin increases IR [21, 22]; moreover,
advanced glycation end products (AGEs) and insulin-like
growth factor-I (IGF-1), which regulate bones, may be also
modiﬁed in T2DM [1, 2]. AGE is formed by elevated blood
glucose levels that cause nonenzymatic glycosylation and
binds to its receptor (RAGE) which activates transcription
factor nuclear factor-κB (NF-κB). This results in increased
expression of receptor activator of nuclear factor kappa-B
ligand- (RANKL-) mediated osteoclastogenesis [23, 24].
Accumulation of AGE may also stimulate interleukins (IL)
such as IL-6, which reduces osteoblast proliferation and
activity while increasing osteoclastic activity [1, 25–29]. In
T2DM patients, there is hypersecretion of calcium and
decreased calcium absorption due to decreased vitamin D
levels and estrogenic levels, especially in females [30].
In addition, drugs used to treat diabetes can also have an
eﬀect on bone health. One such group of drugs is thiazolidiones (TZD), which increases the risk of osteoporosis in
T2DM patients. TZDs are capable of inﬂuencing the mesenchymal cells to diﬀerentiate more into adipocytes rather than
osteoblasts which results in increased cortical porosity [31].
Furthermore, insulin is administered to diabetic patients to
help lower circulating glucose which directly acts on osteoclasts. A review of the drug eﬀects on bone can be found in
Montagnani et al. [1]. Although metformin has been shown
to reduce bone loss, based on the severity of the side eﬀects
caused by this drug [32], absorption of nutrients essential
for bone health may be compromised [30].

2. Materials and Methods
In this review, we are presenting information on the interaction of diﬀerent pathways that inﬂuence bone, glucose
utilization, and insulin signalling pathways. We collected literature using the following search engines: PubMed, Google
Scholar, Cochrane Reviews, and Medline. The keywords used
for the search were type II diabetes, insulin, bone, insulin and
osteoclasts, insulin and osteoblasts, insulin and Wnt, insulin
and inﬂammation, and insulin and oxidative stress.

3. Results and Discussion
3.1. Insulin Signalling Pathway under Normal and Diabetic
Conditions. Normally, insulin activates several cascades of
intracellular signalling pathways, which begins with phosphorylation of insulin receptor substrate 1 & 2 (IRS-1 & 2)
and is followed by activation of phosphotidylinositide 3
kinase (PI3-K) and protein kinase B (AKT). This series of
phosphorylation events, in turn, deactivates forkhead box proteins (FOX) and phosphorylates glycogen synthase (GSK),
which plays an important role in controlling gluconeogenesis,
glycogenolysis, and maintaining glucose homeostasis [33]
(Figure 1). In vitro DNA-binding assays and transfection
experiments showed that both mammalian FoxO and FoxA
proteins can bind to IRS and mediate transcriptional activation [34].
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Figure 2: Insulin signalling pathway in cells of patients with type 2 diabetes mellitus.

Insulin regulates the transcriptional activity of hundreds
of genes involved in glucose and lipid metabolism in the
liver. Insulin along with growth hormone activates serine/
threonine protein kinase (AKT), AKT phosphorylate FOXOs,
and causes retention of FOXOs in the cytoplasm. In response
to stress, decreased insulin, and growth hormone, FOXOs
are activated and mediate bone cell functions [35, 36]. In
T2DM, due to IR, there is decreased phosphorylation of IRS
1 & 2, decreasing PI3-K and increasing mitogen-activated
protein kinase (MAPK) activation. This results in increased
FOXO1 [33] (Figure 2). FOXO1 is activated in tissues associated with diabetic complications such as wound healing
and bone fractures [33].
FOXOs play an important role in maintaining skeletal
homeostasis by mediating both osteoclast and osteoblast
function [35–41]. Other proteins like AGE, proinﬂammatory
cytokines, and reactive oxygen species (ROS) are increased
with high circulating blood glucose [33]. In T2DM, prolonged high levels of proinﬂammatory cytokines such as
TNF-α, IL-1β, IL-6, and IL-18 enhance lipid peroxidation
and dyslipidemia, resulting in increased osteoclastogenesis
[42–44]. High levels of TNF-α increase the RANK/osteoprotegerin (OPG) ratio which enhances bone resorption [45].
Increased AGE, ROS, and proinﬂammatory cytokines
increase bone loss. When AGE is formed, it bonds to its
receptor RAGE and activates nuclear factor-κB (NF-κB)
resulting in increased expression of RANKL-mediated osteoclastogenesis [23, 24, 46]. Prolonged inﬂammation also stimulates the expression of proapoptotic genes such as bcl-2-like

protein (Bax). This reduces the expression of genes that
stimulate osteoblast formation such as Fos-related antigen
(FRA-1) and Runt-related transcription factor (RUNX2)
[33] resulting in decreased bone formation. Oxidative stress
reduces diﬀerentiation to osteoblasts and can directly
degrade bone [47]. NF-κB responds to oxidative stress and
increases osteoclast activity and decreases osteoblast diﬀerentiation [47].
3.2. Type 2 Diabetes Modulation of Bone Marrow Stem
Cells. The microenvironment in bone marrow cells is aﬀected
by complications of diabetes. The mesenchymal stem cells
(MSC) can diﬀerentiate into adipocytes or osteoblasts
depending on the prevailing signalling molecules. Longstanding diabetes causes disruption of the bone marrow
microenvironment by depleting and altering stem/progenitor cells resulting in enhanced adipogenesis and depressed
osteogenesis [3, 48–56]. In vitro studies on RAW264.7 cells
have demonstrated that high glucose decreases autophagy
of osteoclasts thereby increasing osteoclastogenesis [57].
The multifactorial causes of enhanced adipogenesis are
augmented insulin signalling, hyperlipidemia, and ROS.
One of the major players is peroxisome proliferator-activated
receptor gamma (PPARγ), an important regulator of lipid,
glucose, and insulin metabolism. It consists of two isoforms—PPARγ1 and PPARγ2. PPARγ2 regulates the differentiation of MSC to either adipocytes or osteoblast
[58]. Inside the cells, high levels of blood glucose activate
phosphatidylinositol 4,5 bisphosphate 3 kinase (PI3k) and
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phosphorylate protein kinase B (PKB). This decreases peroxisome proliferator-activated receptor gamma (PPARγ)
through FOXO1 and increases adipogenesis.
Activation of mechanistic target of rapamycin (mTOR)
increases adipocyte speciﬁc factors in preadipocytes and
increases muscle satellite cells [33]. The PI3K/PKB pathway is also stimulated by oxidative stress generated by
ROS and enhances adipogenesis, thereby decreasing osteoclastogenesis [55].
3.3. FOXO1 Regulates RANKL-Mediated Osteoclastogenesis.
FOX-1 is a transcription factor that mediates RANKinduced osteoclast formation. Osteoclast formation includes
several steps such as diﬀerentiation of myeloid precursors
to preosteoclasts, fusion of mononuclear preosteoclast to
multinucleated osteoclasts, and maturation and activation
of osteoclasts. Several proteins are involved in osteoclastogenesis such as RANKL, NK-κB, TNF, macrophage colony
stimulating factor (M-CSF), and nuclear factor of activated
T cells (NFATC1) [36]. Initially, M-CSF binds to its receptor,
which upregulates and activates RANK and NF-κB in
osteoclast precursor cells. RANK signalling stimulates the
formation of single-cell tartrate-resistant acid phosphatase(TRAP-) positive preosteoclasts, which fuse together to form
the multinucleated TRAP-positive osteoclast [34].
Cell fusion is the most important step in osteoclastogenesis and dendritic cell-speciﬁc transmembrane protein
(DC-STAMP), which induces NFATC1, the master gene
in osteoclastogenesis [33]. Other NFATC1-mediated fusion
molecules are TRAP, osteoclast-associated receptor (OSCAR),
Cathepsin K, proto oncogene tyrosine protein kinase (C-SRC),
and β3 integrin. Cell fusion can also be induced by other
molecules independent of NFATc1 such as CD9, CD44,
E-cadherin, merlin α, and macrophage fusion receptor
[39]. When RANK stimulates NFATC1 through extracellular signal-regulated kinases (ERK)/c-Jun amino-terminal
kinases (JNK)/MAP kinase p38 [33, 36], it also activates
phospholipase C (PLC). This releases inositol triphosphate
(IP3) which causes extracellular calcium inﬂux and intracellular calcium release inducing calcium oscillation.
These calcium oscillations activated by NFATc1 are regulated by Transmembrane 64 (Tmem 64) and interact with
sarcoplasmic endoplasmic reticulum carbonic anhydrase
(SERCA), causing osteoclast diﬀerentiation [59]. Tmem64
also interacts with SERCA2 through tyrosine-based activation motif (ITAM) that has a common Fc receptor gamma
subunit (FCRγ) and DNAX-activating protein 12 (DAP12).
This costimulation leads to activation of phospholipase
gamma (PLCγ) and IP3 causing calcium release from endoplasmic reticulum (ER), generating calcium oscillations.
These oscillations activate Ca2+/calmodulin-dependent protein kinase (CaMK) IV and cyclic AMP response elementbinding protein (CREB), which plays an important role in
the generation of mitochondrial ROS, induction of NFATc1
and C-FOS necessary for osteoclast production. NFATc1
induced by CREB is short acting but continuously spike
cycling Ca2+ by activating SERCA2, which is necessary to
sustain NFATc1 activity during osteoclastogenesis [38].
Later, osteoclasts are polarized by actin, integrin αV, and
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integrin β3, which activates vacuolar ATPase and release of
cathepsin K (CTSK), lysosomal cysteine, and protease to
degrade bone matrix, causing bone resorption.
FOX-1 which mediates the eﬀect of RANK on osteoclastogenesis also modulates Toll-like receptor (TLR) and
cytokine production in monocyte and dendritic cells as
well as downstream regulation of NFATC1. This, in turn,
regulates dendritic cell-derived protein (DC-STAMP) and
ATP 6VOD2, which play an important role in cell fusion
[33]. The diﬀerentiated osteoclast expresses NFATc1, OSCAR,
CTSK, and PPARγc1b. In diabetic conditions, increased
RANKL/OPG ratio contributes to increased osteoclastogenesis [35]. Interestingly, in the absence of RANK, NF-κB can be
activated by TNF receptor-associated factor 6 (TRAF6) pathway, ectopic NFATC1, and activated RANKL promoters [41].
3.4. Role of FOXOs against Oxidative Stress in Osteoblasts.
FOXOs protect osteoblasts from oxidative stress by interacting with transcription factor which regulates amino acid
import, proliferation of osteoblasts, and generation of antioxidant enzymes such as catalase, superoxide dismutase (SOD),
and glutathione [40]. In response to oxidative stress generated by reactive oxygen species (ROS), FOX 1, 3, and 4 are
activated in the nucleus of the osteoblasts and produce antioxidants to decrease bone resorption. Oxidative stress is the
critical step for osteoclast diﬀerentiation and function [35].
Both FOX1 and activating transcription factor 4 (ATF4)
are located in the cytoplasm and respond to stress. Both are
translocated to the nucleus which promotes protein and
amino acid synthesis. ATF4 controls protein synthesis
through a negative feedback mechanism that leads to accumulation of glutathione and collagen production. FOX1 also
promotes osteoblast proliferation by increasing cell cycle
cyclin D1 and D2 and suppressing cell cycle inhibitor
p27Kip1. Decreased FOX1 suppresses osteoblastogenesis by
decreasing osterix and type 1 collagen protein levels but does
not aﬀect levels of Runx2 and Bsp (bone sialoprotein) [40].
FOXOs are potent repressors of osteoblastogenesis by also
decreasing PPAR-γ [37, 40]. This increase in bone resorption
may be attributed to activation of antiosteoclastogenic factor
osteoprotegerin (OPG) which promotes FOX-mediated
transcription of β-catenin/T-cell speciﬁc transcription factor
(TCF), thereby promoting RANK-mediated osteoclastogenesis by increasing PPAR-γ. This increases apoptosis of osteocytes and enhances adipogenesis as indicated by decreased
bone markers such as calcitonin, TRAP, and cathepsin K
[37]. Osteoblasts exposed to oxidative stress also have
decreased expression of RUNX2 and osteocalcin and
increased adipogenesis-related factors PPAR-γ and fatty acid
binding protein-4 (FABP4) [55].
3.5. Wnt/β-Catenin Pathways in Metabolic Syndrome. Activation of Wnt (β-catenin) signalling promotes diﬀerentiation
of progenitor stem cells into osteoblasts and prevents adipogenesis. Regulation of Wnt signalling is a balance between
adipogenesis and myogenesis [60]. Wnt/(β-catenin) is activated when PPAR-γ binds with lymphoid enhancer factor/
T cell factor (LEF/TCF), binding domain of β-catenin, and
facilitates its phosphorylation by glycogen synthase kinase3b
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(GSK3b), thereby resulting in increased diﬀerentiation
within preadipocytes [61, 62]. The Wnt family has 19 ligands,
10 Wnt receptors, frizzled (Fz) coreceptors, and low-density
lipoprotein receptor-related proteins (LRP-5 and LRP-6).
The actions of Wnt include canonical and noncanonical
pathways. Noncanonical Wnt signalling cascade also plays
an important role in adipogenesis. Wnt binds to its receptor
and activates phospholipase C (PLC), generating diacylglycerol (DAG) and inositol triphosphate (IP3), which results in
the release of intracellular calcium from the endoplasmic
reticulum. Eﬄux of intracellular calcium activates protein
kinase C (PKC). This leads to the phosphorylation of SET
domain bifurcated-1 (SETB1) histone methyltransferase,
inhibiting PPAR-γ through histone methylation H3-K9,
and upregulates RUNX2 required for osteoblastogenesis
[63, 64]. PKC has a dual role in adipogenesis. Its isoforms
α, δ, and μ inhibit adipogenesis, while β1 and γ isoforms promote adipogenesis. Hyperglycemia-induced noncanonical
Wnt pathway increased adipogenesis through activation of
various PKC isoforms [55]. Wnt/β catenin pathway inhibitor, sclerostin, is increased in the serum of T2DM and is
inversely related to levels of bone turnover markers [65, 66].
Regulation of Wnt signalling is a balance between adipogenesis and myogenesis. Insulin action and insulin resistance
can be modulated by Wnt and lipoprotein receptor-related
protein 5 (LRP5) activity [57]. Wnt canonical pathway acts
on Fz/(LRP5/6), decreasing GSK-3β and increasing βcatenin, which translocates to the nucleus, conjuncts with
lymphoid enhancer factor/T-cell factor (TCF), and regulates
transcription of Wnt target genes. The in vitro study using
human adipose-derived stem cells has shown that during
the diﬀerentiation of insulin-producing cells (IPC), protein
levels of Wnt 1, β-catenin, and GSK3β are increased [67].
At the same time, TCF-1 and cyclin-D increased from day
1 to day 9 and decreased from day 9 onwards and continued
to decrease. Inhibition of Wnt signalling does not decrease
diﬀerentiation from day 1 to day 9 but upregulates IPC speciﬁc markers such as insulin promoter 1 (PDX-1), insulin,
and insulin receptor substrates 1 and 2 (IRS-1 and 2) from
day 9 to day 12. Wnt signalling speciﬁc marker such as
glucokinase decreased from day 9 to day 12. Activation
of Wnt signalling on day 9 decreases IPC speciﬁc markers,
and deactivation of Wnt signalling is necessary for IPC
maturation [39, 67]. Overall, Wnt signalling may be more
involved in IPC maturation [58]. In the pancreas and
hepatocytes, β catenin/Wnt signalling pathways activate
glucokinase promoter activities in the presence of PPAR-γ
and cyclin-D promoter with transcription factor 7-like 2
(TCF7L2) binding sites [68] and play an important role in
maintaining β-cell function [69].
IRS-2 and Akt are key signalling molecules in maintaining β-cell mass [70]. Akt prevents free fatty acid-induced βcell apoptosis through inhibition of proapoptotic proteins
like germinal center kinase 3α, β(GCK3α/β), FOX 1, and
p53 [70]. The cross talk between insulin and Wnt signalling
occurs at the level of coreceptor LRP 5, which has a profound
positive eﬀect on insulin signalling in preadipocytes [71].
The direct interaction between insulin receptors and
LRP 5 occurs in an insulin/Wnt inducible manner. Insulin
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receptor/LRP 5 plays an important role in the pathogenesis of IR and obesity. Decreased Wnt canonical pathway
receptor LRP5/6 increases the risk of diabetes mellitus
and impaired glucose intolerance [33, 60].
Wnt signalling varies slightly in diﬀerent cells. In preadipocytes, both insulin and Wnt3a lead to phosphorylation of LRP 6, GSK3b, Akt, and extracellular signal-regulated
kinase (ERK1/2). If both IGF receptors and insulin receptors decrease, insulin-mediated Wnt3a phosphorylation
decreases. Whereas, Wnt-mediated phosphorylation decreases
not only when insulin receptors and IGF receptors are
decreased but also in the absence of these receptors.
In skeletal muscles, Wnt/β-catenin signalling (1)
increases muscle-speciﬁc myogenic transcription factor, (2)
decreases PPAR-γ-related adipogenesis and C/EBP α
expression, (3) converts type 2 skeletal muscle ﬁbers into
type 1 muscle ﬁbers, (4) decreases c-myc-mediated activation of p27, which decreases myogenesis and increases adipogenesis, and (5) activates mitogenic factor 5 (Myf 5),
which in turn activates myoblast determination protein D
(myoD) [72, 73]. Risk of T2DM increases with decreased
Wnt signalling in the skeletal muscle and increased adipogenesis [55, 74].
In hepatocytes, canonical Wnt3a stimulation decreases
key enzymes of gluconeogenesis such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase
(G6Pase). Noncanonical Wnt 11 stimulation decreases
glucose output by hepatocytes. Insulin increases TCF7L2,
which increases cyclin D, a downstream target of the Wnt
signalling pathway [75]. β-Catenin phosphorylation is positively correlated with transcriptional activity of β-cat/TCF.
β-catenin phosphorylation occurs with (1) protein kinase A
(PKA) activation; (2) PKA/cyclic adenosine monophosphate
(cAMP) activator and glucagon stimulate cAMP responsive
element-binding protein (CREB) phosphorylation, and (3)
insulin is able to stimulate β-catenin phosphorylation [76].
In response to feeding, insulin mediates a repressor eﬀect
on gluconeogenesis through TCF7L2 and β-catenin phosphorylation. In the absence of TCF7L2, insulin also decreases
gluconeogenesis by attenuating FOX [77]. Wnt and TCF7L2
are negative regulators of gluconeogenesis, while FOX is a
positive regulator of gluconeogenesis [76]; insulin increases
TCF7L2 in intestinal L-cells and stimulates the expression
of proglucagon gene and incretin hormone glucagon-like
peptide 1 (GLP-1) [77]; glucagon increases FOX through
cAMP, and insulin decreases FOX through PI3K/Akt-mediated nuclear exclusion of FOXO1 [78], and TCF7L2 increases
hepatic glucose production and the risk of T2DM [77].
3.6. Hormonal Balance in Skeletal Homeostasis and Metabolic
Syndrome. Certain hormones associated with bone metabolism and energy balance such as osteocalcin, leptin, and
adiponectin aﬀect insulin signalling pathways and other
hormones related to calcium homeostasis [70]. Osteocalcin
is the marker of osteoblast activity [79] and is modulated
in the osteoblast-speciﬁc gene esp, which encodes osteotesticular protein tyrosine phosphatase (OST-PTP) [80]. This
OST-PTP dephosphorylates the insulin receptor [79].
Decreased OST-PTP increases insulin signalling through
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Table 1: Eﬀects of antidiabetic drugs on bone metabolism.

Antidiabetic drugs
Amylin
Incretin
Insulin
Metformin
Sodium glucose cotransporter inhibitors
Sulfonylureas
Thiazolidinediones

Mode of action

References

At low concentrations ⬇ osteoclastogenesis
⬇ GLP-1 receptors; ⬆ GIP inﬂuence on bone
resorption and bone formation
⬆ Bone formation
⬇ Indigenous glucose production; ⬆ insulin
sensitivity; ⬆ osteogenic markers
Interferes with calcium and phosphate
homeostasis; ⬆ CTX and ⬇ BMD
⬇ CTX, NTX; ⬆ ALP, osteocalcin, bone strength
⬆ Adipogenesis; ⬇ BMD

[90]
[30, 71, 86]
[87–89]
[31, 51, 78, 79, 80–82]
[91, 92]
[30, 81, 83]
[31]

⬆ = increases; ⬇ = decreases. GLP-1 = Glucogon like peptide 1, GIP = G;ucose-dependent insulinotropic polypeptide, CTX = C-terminal telopeptide,
NTX = N-terminal telopeptide, BMD = bone mineral density, ALP = alkaline phosphatase.

the insulin receptor and promotes pancreatic β-cell proliferation, while increasing insulin and insulin-sensitizing adiponectin [79, 81].
Leptin produced by adipocytes acts on the hypothalamus,
which regulates decreases and increases on appetite and satiety, as well as decrease in bone formation by inhibiting osteocalcin production in new bones [82, 83]. Adiponectin, also
produced by adipocytes, acts on bones in an age-dependent
manner and is inversely proportional to BMD [84]. Adiponectin is an antagonist to leptin, acts on the brain, and
increases sympathetic output to peripheral osteoblast [85].
Other hormones like vitamin D and estrogen levels may
be associated with developing T2DM and IR [65, 86].
Decreased levels of vitamin D decrease renal reabsorption
of calcium and reduce osteocalcin production by osteoblasts
[87], resulting in diminished bone formation. Estrogen, on
the other hand, is implicated in IR. Of the two estrogen
receptors, ERα is positively associated with glucose metabolism [88]. Both direct and indirect eﬀects of ERα on IR have
been reported. Directly, ERα can act on insulin signalling and
increase GLUT4 expression, while indirectly, it can modulate
oxidative stress and inﬂammation [89].
3.7. Inﬂuence of Drugs Used for Treating Diabetes and Bone.
Diﬀerent drugs commonly prescribed for treating diabetes
like metformin, thiazolidinedione, and sulfonylurea do aﬀect
bone mass (Table 1). Most of them act on diﬀerent pathways
to inﬂuence bone status in the patients. One highly prescribed medication for T2DM patients is metformin. This
drug has been associated with the most bone protective properties. Metformin can activate adenosine monophosphate
kinase (AMPK) to reduce indigenous glucose production or
may also act independent of the AMPK pathway by inhibiting glycolytic enzymes or adenylate cyclase and decreases
gluconeogenesis [90, 91]. At the mesenchymal cellular level,
metformin reduces adipocyte formation in the bone marrow
by preventing endothelial nitric oxide synthase (eNOS)
expression [14]. Metformin acts as an insulin sensitizer,
increases GLP-1 secretion in L-cells of the intestines, stimulates nuclear translocation of β-catenin, and increases transcription of luciferase reporter gene. GLP-1 increases (1)
pancreatic insulin secretion, (2) proinsulin gene expression,

and (3) β-cell mass. GLP-1 also decreases gastric emptying
and glucagon release. Inside the cells, metformin increases
IRS-2, p-PI3K, p-PKB, calcium/calmodulin-dependent protein kinase 2 (CaMK2), CREB, p-GSKSβ (inactive form),
enzymes of glycolysis like phosphofructokinase (PFK), and
Kreb’s cycle enzymes (isocitrate dehydrogenase, malate
dehydrogenase). Glucose utilization mediated by metformin
is through calcium-dependent protein kinase [55]. Metformin also increases the markers of osteogenic diﬀerentiation
and function [33]. Although metformin has beneﬁcial
eﬀects on bone, there is concern for patients who have
moderate to severe digestive intolerance after consuming
this medication, as nutrients necessary for bone health may
not be absorbed properly.
Sulfonylureas are organic compounds that act on the pancreatic cells and increase the release of insulin. They act on
membrane channels, ﬁrst by blocking the potassium channels,
causing depolarization in the cell which then opens the Ca2+
channels and this increases the release of insulin [92]. There
are very few studies that show the interaction between the consumption of these drugs and bone. The few reports show that
C-terminal telopeptide (CTX) and N-terminal telopeptide
(NTX) levels are decreased in patients who take these drugs
[32, 93]. Sulfonylureas can also activate the PI3K/ATK pathway which then increases the expression of alkaline phosphatase and osteocalcin mRNA expression [94]. It has been
reported that sulfonylureas protect against ovariectomyinduced bone loss and also increase the mechanical strength
by increasing bone formation [95]. Based on the limited
evidence available, sulfonylureas are beneﬁcial to the bone.
In-depth, long-term studies are necessary to know the exact
function of sulfonylureas on the bone in T2DM patients.
Recently, incretin-based therapies are being used. Incretins are inhibitors of glucagon-like peptide 1 receptors (GLP1) and dipeptidyl peptidase 4 (DPP-4). GLP-1 receptors are
expressed in the pancreatic β cells and other cells promoting
metabolic activity [32]. It has been reported that GLP-1 can
control bone resorption by interacting with GLP-2 and
glucose-dependent insulinotropic polypeptide (GIP) [96]. In
addition, it can also act on a calcitonin-dependent pathway
[96]. GLP-2 may have antiresorptive function [97] while GIP
can inﬂuence bone resorption and bone formation [80, 98].
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Many clinical studies with patients who are on insulin
treatment for T2DM have reported increased risk of fracture,
especially in postmenopausal women [99–101]. Insulin is
known to increase bone formation generally, and lack of
detailed study on the reasons for insulin increasing fracture
rates is not understood.
Amylin is a peptide that is reported to have some eﬀects
on bone metabolism [32]. Both in vitro and in vivo studies
show this peptide, when present in lower levels, is associated
with inhibited osteoclastic activity [102]. However, there is
not much data on clinical studies regarding the eﬀects of
amylin on the bone.
Sodium glucose cotransporter inhibitors (SGCT) are
drugs that reduce the reabsorption of glucose from the
kidneys by inhibiting the sodium glucose cotransporters.
They are capable of altering the calcium and phosphate
homeostasis; therefore, they aﬀect the bone and may be
more deleterious to the bone. Several reports have shown
that imbalance in the calcium and phosphate homeostasis
triggers secretion of PTH which increases bone resorption
[103]. Increased levels of CTX and decreased BMD values
are also reported with the use of these drugs [104]. However, some reports have not shown any signiﬁcant inﬂuence on the mineral levels or the levels of parathyroid
hormone (PTH) and vitamin D [105, 106]. This may be
due to any diﬀerences in the intake of vitamins and minerals. At this point, it may be safe to say that these drugs
may be deleterious to the bone although more in-depth
studies are required to determine the mechanism by which
these drugs aﬀect the bone [32].
TZDs are the most popular set of drugs that are proven to
be harmful to the bone. The primary mechanism of action in
TZDs is through direct induction of PPAR-γ leading to
improved insulin sensitivity. The stimulation of diﬀerentiation of multipotent stem cells into adipocytes and increased
adiposity in bone marrow are seen in patients treated with
TZDs. The most common side eﬀect of TZDs is weight gain
through promotion of PPAR-γ, with increased adipogenesis
leading to increased subcutaneous and bone marrow fat
depots and decreased bone formation. These properties of
TZDs make the patients’ bones become very fragile, and their
BMD is signiﬁcantly decreased [33].

4. Conclusion
There is increasing evidence about the interaction between
the glucose metabolic pathway, insulin signalling, and bone
metabolic pathways. In 2015, it was reported that there was
a rise in people aged 66 and older having T2DM [107].
Unfortunately, this is also the age when both men and
women have decreased bone mass and are at high risk of having hip and spine fractures [65]. This may be because of the
interaction of signalling pathways that modulate bone and
glucose metabolism in T2DM patients. In order to assess
the fracture risk, a combination of BMD, FRAX, and biochemical markers should be used. T2DM patients should be
tested for their bone health regularly, and bone status in
T2DM patients should be recognized as a complication of
diabetes as recommended by Sanches et al. [58]. Another

7
factor that inﬂuences the bone in T2DM is as a side eﬀect
of the drugs that are prescribed to treat diabetes. It is important to note that there is an intricate connection between the
diﬀerent pathways that are altered in T2DM patients and
bone metabolism. Although there is evidence of the eﬀects
of metformin and TZDs on bones, more research need to
be conducted with the newer antidiabetic drugs. Therefore,
patients being treated for diabetes should be tested for several
vitamin and mineral levels. This information should be used
to advise patients on the nutrient intake of speciﬁc vitamin
and mineral deﬁciencies. In addition, medications used for
treating diabetes should be carefully chosen, and any micronutrient deﬁciency should be supplemented.
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